Welcome to TrypTamine Therapeutics Limited

A precision approach to psychedelic medicine

Exploring innovative solutions in psychedelic
drug development for enhanced patient care.

Tryptamine Therapeutics

Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. Tryptamine Therapeutics intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin) which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field. Tryp’s lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. 

Leading the Way in Therapeutic Innovation

With A Focus On:

Eating Disorders
Chronic Pain

ASX Filings

Read about Tryptamine Therapeutics Limited on the ASX

Photo Of People Near Wooden Table

Our Leadership

Our leaders bring an enormous breadth and depth of proven experience in building companies in the pharmaceuticals sector.

Significant opportunities for investors